Clinical trials have helped hundreds of thousands of people – who are alive today – because new, more effective treatments became available. It’s important to take charge of your health and educate yourself about clinical trials you are eligible for based on your current situation.
Get matched to a prostate cancer clinical trial that’s right for you! Print out your results to discuss with your treatment team, or contact the study coordinators directly.
Featured Clinical Trials
Below are featured clinical trials you may be interested in learning more about. Be sure to use ZERO’s clinical trial finder above or visit www.clinicaltrials.gov to learn about all prostate cancer clinical trials you may be eligible for. You can use the results of these clinical trial finder tools to have conversations with your doctor.
The PROMISE Study
PROMISE is an important new research study that brings precision medicine to the fight against prostate cancer. The study is a long-term collaboration between researchers, doctors, and patients to improve knowledge and understanding of the critical role of germline genetic mutations (inherited genes) in men with prostate cancer. (Precision medicine is an approach to tailoring disease prevention and treatment that takes into account differences in people’s genes, environments, and lifestyles, it can be contrasted with a “one size fits all” approach that focuses on an average person without consideration of individual differences)
The PRESERVE Clinical Trial
Now enrolling – The PRESERVE clinical trial is evaluating the use of the NanoKnife System as a focal therapy option for prostate cancer patients. It will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk (Gleason score of 3+4 or 4+3) prostate cancer patients. More information about participation is available on the study website.
The SPLASH Clinical Trial
Now enrolling – the SPLASH clinical trial is studying a potential treatment for metastatic Castration-Resistant Prostate Cancer (mCRPC). Patients who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT) and who are ineligible or are electing not to receive treatment with chemotherapy treatment may be eligible. The study is looking at whether [Lu-177]-PNT2002, a radioligand therapy (RLT), is a safe and effective option to slow down the progression of mCPRC. More information about the trial is available on the website.